Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2020 06:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update

NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
April 03, 2020 06:58 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority

NEW YORK and PETACH TIKVAH, Israel, April 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative...
April 01, 2020 09:00 ET | Source: BrainStorm Cell Therapeutics Inc.

David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer

International Pharmaceutical Veteran to Lead Global Business and Commercial Development Ralph Kern, MD, MHSc, Promoted to President NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell...
March 31, 2020 04:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Appoints Renowned Distinguished Economist, Prof. Jacob Frenkel, Chairman of the Board of Directors

NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced the...
March 16, 2020 03:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19

Funding Secured and Senior Management Team Activated by CEO to Ensure Advancement of all Operational Activities and Completion of Corporate Clinical Milestones Call Time: Wednesday, March...
March 06, 2020 09:25 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share

NEW YORK, March 06, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced that it has...
February 27, 2020 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial

NEW YORK and BOSTON, Feb. 27, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
February 18, 2020 07:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019

NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces...
February 17, 2020 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm’s Chief Operating Officer to Present at Noble Capital Markets’ Sixteenth Annual Investor Conference

NEW YORK, Feb. 17, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases,...
February 11, 2020 06:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS

NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc., (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...